122 results found.
          
2Q13 Revenue: Medtronic
(for FY1Q14 ended 7/26/13) $765MM, -1% (U.S. $536MM, -4%; ex-U.S. $229MM, +5%) Core Spinal $641MM, +1% (U.S. $426MM, -1%; ex-U.S. $215MM, +4%) BMP $124MM, -11% (U.S. $110MM, -14%; ex-U.S. $14MM, +15%)  
BARE BONES® - May 21, 2013
Medtronic posted fiscal year 2013 (ended 4/26/13) spinal revenue of US $3,131MM, -3% from 2012. (Core Spine $2,603MM, flat; BMP $528MM, -15%) (Source:
1Q13 Revenue: Medtronic
For fiscal year 2013 ended 4/26/13 $3,131MM, -3% (U.S. $2,190MM, -5%; ex-U.S. $941MM, +1%) Core Spine $2,603MM, flat (U.S. $1,722MM, flat; ex-U.S. $881MM, +1%) BMP $528MM, -15% (U.S. $468MM, -17%; ex-U.S. $60MM, flat)
BARE BONES® - April 30, 2013
NuVasive announced 1Q13 revenue of US $159.5MM, +5.2% from 1Q12, as well as a $7.5MM upfront partial settlement payment in ongoing litigation with Medtronic regarding cervical plate pa...
1Q13 Revenue: NuVasive
$159.5MM, +5% (Ex-U.S. +47%; U.S. cervical +13%, U.S. lumbar +1%, U.S. biologics -2%, U.S. monitoring services +3%) Will make a $7.5MM upfront partial settlement payment in ongoing litigation with Medtronic regarding cervical plate patents, and gain broad access to Medtroni...
BARE BONES® - February 19, 2013
Medtronic reported 3Q13 (ended 1/25/13) spinal revenue of US $753MM, -3% from 3Q12. (U.S. $522MMMM, -6%; ex-U.S. $231MM, +1%; Core Spinal $639MM, flat; Biologics $114M...
4Q12 and 2012 Revenue: Medtronic
(for 3Q13 ended 1/25/13) $753MM, -3% (U.S. $522MM, -6%; ex-U.S. $231MM, +3%) Core Spinal $639MM, flat (U.S. $422MM, -1%; ex-U.S. $217MM, +3%) Biologics $114MM, -21% (U.S. $100MM, -22%; ex-U.S. $14MM, -7%) Excluding kyph...
BARE BONES® - November 20, 2012
For 2Q13 (ended 10/26/12), Medtronic reported spinal revenue of US $782MM, -5% from 2Q12. (U.S. $549MM, -8%; ex-U.S. $233MM, +2%) (Core Spinal $649MM, -2%; BMP $133MM,...
3Q12 Earnings: Medtronic
(For 2Q13 ended 10/26/12) $782MM, -5% (U.S. $549MM, -8%; ex-U.S. $233MM, +2%) Core Spinal $649MM, -2% (U.S. $430MM, -4%; ex-U.S. $219MM, +3%; U.S. Navigation +35%) BMP $133MM, -19% (U.S. $119MM, -20%; ex-U.S. $14MM, -7%)   ...
Final 2Q12 Results
ORTHOWORLD’s estimates place 2Q12 market growth at 5% over 2Q11, as shown in Exhibit 1. Performance highlights follow and pertain to 2Q12, unless otherwise noted.  Exhibit 1 Ort...
BARE BONES® - August 21, 2012
Medtronic posted 1Q13 (ended 7/27/12) spinal revenue of US $786MM, -3% from 1Q12. (Core Spinal $645MM, +1%, Biologics $141MM, -19%) Growth reflects constant currency. FY12 Other Biologics reve...
Final 1Q12 Results
ORTHOWORLD’s estimates place overall 1Q12 market growth at 4% over 1Q11, as shown in Exhibit 1. Performance highlights follow and pertain to 1Q12, unless noted otherwise. Exhibit 1 Orthopaedic Sales1 Increas...
BARE BONES® - May 22, 2012
Medtronic posted fiscal year 2012 (ended 4/27/12) spinal revenue of US $3,267MM, -4% from 2011, and FY4Q12 spinal revenue of $818MM, -6%. (FY12 Core Spinal $2,467MM, -...
Continuing 2011 Results, Including AAOS Conference Highlights
The orthopaedic industry appears to be tilting its focus from implant materials and toward implant alignment and personalization, per analyst review of the 2012 meeting of the American Academy of Orthopaedic Surgeons (AAOS). On the floor and in recent earnings calls, companies noted observatio...
The Next Look at 2011 Results
ORTHOWORLD’s preliminary estimates place overall 2011 market growth at 5% over 2010, as displayed in Exhibit 1. Performance highlights follow, and address both 4Q10 and 2011, as indicated.                                      ...
Final 3Q11 Results: Medtronic
MEDTRONIC (for 2Q12, ended 10/28/11) $839MM, -3% (U.S. $599MM, -7%; ex-U.S. $240MM, +8%) • Core Spinal $631MM, -3% (U.S. $414MM, -7%; ex-U.S. $217, +6%; Hardware -1%, Balloon kyphoplasty -8%) • Biologics $208MM, -4% (U.S. $185MM, -8...
3Q11: A First Look at Financials: RTI Biologics
RTI BIOLOGICS $28.4MM, +8% * Sports Medicine $11MM, +2% (U.S. +3%) * Spine $10.3MM, +6% * Bone Growth Substitute/General Orthopaedic (BGS/GO) $7MM, +24% * Spine growth attributed to inventory replenishment from a few smaller distribu...
Final 2Q11 Results: Medtronic
MEDTRONIC (for 1Q12, ended 7/29/11) $825MM, -3% (U.S. $589MM, -7%; ex-U.S. $236MM, +7%) * Core Spinal $610MM, -5% (U.S. $398MM, -9%; ex-U.S. $212MM, +4%; Metal constructs -3%, Kyphon -13%) * Biologics $215MM, +2% (U.S. $191MM, flat; ex-U.S. $24...
First Look at 2Q11 Results: RTI Biologics
RTI BIOLOGICS $29.3MM, +9% * Spinal $11MM, +34% * Bone Graft Substitutes/General Orthopaedic $6.2MM, -14% * Sports Medicine $12.1MM, +5% (U.S. 7%) * Launched BioAdapt demineralized bone matrix foam * Low growth in Bone Graft/G...
Next Round of 1Q11 Results: Medtronic
MEDTRONIC (for fiscal year ended 4/29/11) $3,414MM, -3% (U.S. $2,553MM, -5%; ex-U.S. $861MM, +3%) * Core Spinal $2,530MM, -4% (U.S. $1,744MM, -7%; ex-U.S. $786MM, +2%) * Biologics $884MM, +1% (U.S. $809MM, flat; ex-U.S. $75MM, +20%) ...
More 2010 Results: Medtronic
MEDTRONIC (for 3Q11 ended 1/28/11) $861MM, +2% (U.S. $646MM, flat; ex-U.S. $215MM, +8%) * Core Spinal $626MM, -1% (U.S. $431MM, -3%; ex-U.S. $195MM, +6%) * Biologics $235MM, +10% (U.S. $215MM, +9%; ex-U.S. $20MM, +36%) *Kyphon -5% fo...
2010 Merger and Acquisition Activity in Orthopaedics and Spine 4Q10: Osteotech
4Q10 OSTEOTECH acquired by MEDTRONIC for $123MM in cash for shares transaction * 2009 sales of $96.6MM; sales multiple of 1.3 * Platform includes Grafton demineralized bone matrix, MagniFuse bone graft and Plexur Bio...
  • ORTHOWORLD INC.
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2019 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group